Abbott Laboratories
ABT
Below: live stock price for Abbott Laboratories (ABT), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Abbott Laboratories (ABT) is a Healthcare company based in United States. Operating in Medical Devices, it employs about 122,000 people. Over the past year ABT traded between 81.97 and 132.03 USD. Trailing P/E sits near 39.48 on a market cap of about 184.98B USD. It currently yields 2.37% in dividends.
- Prev close
- $104.57
- Volume (24h)
- $896.28M
- Market cap
- $184.98B
- Currency
- USD
Score
46/ 100 · Mixed
- Value40
- Quality72
- Momentum24
- Growth25
- Risk79
- Dividend36
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 105.3771 -0.77%
- +20 bars
- 104.2523 -1.83%
- +60 bars
- 103.8203 -2.24%
- +120 bars
- 103.8045 -2.26%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.37% per bar.
Interpretation
Composite signals look mixed. Strength: risk profile with weakness: momentum. Price sits in the middle of the recent range, trend is sloping downward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value40/100
Value looks weak — driven by P/E (39.48).
P/E:39.48P/B:3.6PEG:1.49 - Quality72/100
Quality looks solid — driven by Gross margin (57.08%).
Profit margin:9.75%Gross margin:57.08% - Momentum24/100
Momentum looks fragile — driven by 52w change (-14.24%).
52w change:-14.24% - Growth25/100
Growth looks fragile — driven by Earnings growth (-43.70%).
Revenue growth:14.50%Earnings growth:-43.70% - Risk79/100
Risk looks strong — driven by Debt / equity (63.21).
Beta:0.58Debt / equity:63.21Short interest:1.12% - Dividend36/100
Dividend looks weak — driven by Payout ratio (78.71%).
Dividend yield:2.37%Payout ratio:78.71%
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 27.4%
- Max drawdown
- -36.8%
- Below period high
- -19.6%
- Best day
- +10.71%
- Worst day
- -10.04%
- Up days
- 48%
- Current streak
- 2 up
- Typical day swing
- 2.2%
- Volume vs average
- -3%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 117.34 high → 95.06 low · 60 bars
- ResistanceFib +161.8% extensionnot reached153.389 USD+44.43% from current
- ResistanceFib +100% extensionnot reached139.62 USD+31.47% from current
- ResistanceFib +61.8% extensionnot reached131.109 USD+23.45% from current
- ResistanceFib +27.2% extensionnot reached123.4002 USD+16.20% from current
- ResistanceFib 23.6% retracementtested 6×112.0819 USD+5.54% from current
- ResistanceFib 38.2% retracementtested 6×108.829 USD+2.48% from current
- Current106.2 USD
- SupportFib 61.8% retracementtested 15×103.571 USD-2.48% from current
- SupportFib 78.6% retracementtested 7×99.8279 USD-6.00% from current
- SupportFib −27.2% extensionnot reached88.9998 USD-16.20% from current
- SupportFib −61.8% extensionnot reached81.291 USD-23.45% from current
- SupportFib −100% extensionnot reached72.78 USD-31.47% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $132.03
- 52w low
- $81.97
- 52w change
- -14.24%
- Day high
- $106.85
- Day low
- $104.60
- P/E (TTM)
- 39.48
- Forward P/E
- 17.89
- PEG
- 1.49
- Price / Book
- 3.6
- Beta (5Y)
- 0.58
- Enterprise value
- 211.54B
- EV / Revenue
- 4.39
- EV / EBITDA
- 17.7
- EPS (TTM)
- $2.69
- Forward EPS
- $5.94
- Dividend yield
- 2.37%
- Dividend rate
- $2.52
- Payout ratio
- 78.71%
- Revenue (TTM)
- 48.23B
- EBITDA
- 11.95B
- Total cash
- 5.6B
- Total debt
- 32.72B
- Debt / Equity
- 63.21
- Profit margin
- 9.75%
- Gross margin
- 57.08%
- Shares outstanding
- 1.74B
- Float
- 1.72B
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.58
- less volatile
- 52-week change
- -14.24%
- Short % of float
- 1.12%
- Short ratio (days)
- 1.84
- Debt / Equity
- 63.21
- very high leverage
- PEG ratio
- 1.49
- EV / Revenue
- 4.39
- EV / EBITDA
- 17.7
- Revenue growth
- 14.50%
- Earnings growth
- -43.70%
- EBITDA
- 11.95B
- Total cash
- 5.6B
- Total debt
- 32.72B
- Insider holdings
- 0.49%
- Institutional
- 81.92%
Recent rating changes
- 2026-10-27Argus ResearchBuy → Holddown
- 2026-10-23Wells FargoOverweight → Overweightmain
- 2026-10-22CitigroupBuy → Buymain
- 2026-10-22RBC CapitalOutperform → Outperformmain
- 2026-10-22Wells FargoOverweight → Overweightmain
- 2026-10-22JP MorganOverweight → Overweightmain
- 2026-10-22TD CowenBuy → Buymain
- 2026-10-22BairdOutperform → Outperformmain
Financial documents
- Corporate Changes & Voting Matters8-K2026-10-21
- Corporate Changes & Voting Matters8-K2026-08-20
- Periodic Financial Reports10-Q2026-07-28
- Corporate Changes & Voting Matters8-K2026-07-16
- Annual report of employee stock purchase11-K2026-06-18
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-27
- Periodic Financial Reports10-Q2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-27
- Offering RegistrationsS-82026-04-24
- Corporate Changes & Voting Matters8-K2026-04-17
- Corporate Changes & Voting Matters8-K2026-04-16
- Offering RegistrationsS-82026-03-23
Recent news
- Health Care Roundup: Market TalkThe Wall Street Journal23 hr. ago
- Dexcom Shakes Off Abbott-Tied Malaise As U.S. Wearables Market Takes OffInvestor's Business Dailyyesterday
- Can Abbott Laboratories (ABT) Stay Reasonable As Its Breakup Nears?Simply Wall St.yesterday
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGENGlobeNewswireyesterday
- Capitol Hill's Top Trades: The Hottest Stocks Congress Is Trading Right NowKiplingeryesterday
- Point-of-Care International Normalized Ratio (INR) Testing Market Report 2026 | Secure 10.1% CAGR Gains as Abbott, Roche, Danaher and Siemens Healthineers Scale Home MonitoringGlobeNewswireyesterday
- Perrigo exits infant-formula with sale to MeridianMadeJust Foodyesterday
- AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,00024/7 Wall St.2 days ago
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.